DOD Pancreatic Cancer, Translational Research Partnership Award
ID: 353864Type: Posted
Overview

Buyer

Dept. of the Army -- USAMRAA (DOD-AMRAA)

Eligible Applicants

Unrestricted

Funding Category

Science and Technology and other Research and Development

Funding Instrument

Grant

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/353864
Timeline
    Description

    The Department of the Army, through the US Army Medical Research and Development Command (USAMRAA), is offering the FY24 Pancreatic Cancer Translational Research Partnership Award, aimed at fostering collaborations between clinician investigators and research scientists to advance pancreatic cancer research. This grant encourages innovative partnerships to tackle significant challenges in pancreatic cancer, focusing on areas such as early detection, therapeutic development, and understanding the disease's biology, with an emphasis on addressing health disparities and metabolic disruptions. The total funding available for this initiative is $4.8 million, with an expected four awards, each potentially funding up to $750,000. Interested applicants must submit a pre-application by June 28, 2024, followed by full applications due by October 3, 2024. For further inquiries, applicants can contact the CDMRP Help Desk at help@eBRAP.org or call 301-682-5507.

    Point(s) of Contact
    help@eBRAP.org
    Files
    Title
    Posted
    HT942524PCARPTRPA_GG.pdf
    The Department of Defense (DOD) has issued a funding opportunity for the FY24 Pancreatic Cancer Translational Research Partnership Award under the Congressionally Directed Medical Research Programs. The initiative aims to support impactful research aimed at reducing the burden of pancreatic cancer among military personnel, veterans, and the general public, with a focus on early detection, therapeutic development, and understanding the disease’s biology. The total available funding for FY24 is $15 million, with significant collaboration encouraged between clinician investigators and research scientists. Applicants must address specific focus areas, such as health disparities, metabolic disruptions, and oncogenic signaling in their proposals. The application process includes a two-step submission: a pre-application due by June 28, 2024, followed by full applications due by October 3, 2024. Each proposal must demonstrate the potential for significant clinical impact and collaboration while adhering to rigorous scientific standards. Awards may fund up to $750,000 but involve separate reports for each Principal Investigator (PI). Overall, this funding opportunity emphasizes collaborative approaches in tackling critical challenges in pancreatic cancer research.
    Similar Opportunities
    Department of Defense HIV/AIDS Prevention Program
    Dept. of the Army -- USAMRAA
    The Department of the Army, through the US Army Medical Research and Materiel Command (USAMRAA), is offering a federal grant opportunity titled the Department of Defense HIV/AIDS Prevention Program (DHAPP). This program aims to save lives and prevent HIV infections by supporting the development of interventions and programs within military health systems, particularly in foreign countries, to achieve HIV/AIDS epidemic control. The DHAPP focuses on enhancing military capacity for ownership and behavioral change, aligning with national strategies, and ensuring sustainable HIV prevention and treatment services. Interested applicants can reach out to Ebony Simmons at ebony.s.simmons.civ@health.mil or by phone at 301-619-2105 for further information. The application deadline is September 18, 2027, with an expected seven awards to be made under this cooperative agreement, which does not require cost sharing or matching.
    Academic-Industrial Partnerships for Translation of Technologies for Diagnosis and Treatment (R01 - Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Cancer Institute (NCI), is offering a funding opportunity titled "Academic-Industrial Partnerships for Translation of Technologies for Diagnosis and Treatment (R01 - Clinical Trial Optional)." This initiative aims to foster interdisciplinary research teams that can translate scientific discoveries into practical tools and methods for diagnosing and treating diseases, addressing both clinical and non-clinical challenges. The program is particularly significant for enhancing cancer research and improving patient care outcomes, with a maximum funding amount of $499,000 per year available for projects lasting up to five years. Applications will be accepted starting January 5, 2025, with a closing date of January 8, 2028. For further inquiries, interested parties can contact NIH Grants Information at grantsinfo@nih.gov or visit the opportunity's webpage at https://grants.nih.gov/grants/guide/pa-files/PAR-25-337.html.
    Comprehensive Partnerships to Advance Cancer Health Equity (CPACHE) (U54 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Comprehensive Partnerships to Advance Cancer Health Equity (CPACHE)" aimed at fostering collaborations between institutions serving underserved populations and NCI-designated Cancer Centers. The initiative seeks to enhance cancer research capacity, promote workforce diversity, and implement community outreach initiatives to address cancer health disparities. This program is vital for developing comprehensive research projects that include administrative cores, research education, and outreach efforts, ultimately contributing to a stronger national cancer program. Eligible applicants can request funding of up to $2.2 million over five years, with the application submission period starting on December 15, 2023. For further inquiries, interested parties can contact NIH Grants Information at grantsinfo@nih.gov.
    National Cancer Institute Program Project Applications for the Years 2023, 2024, and 2025 (P01 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health, through the National Cancer Institute (NCI), invites applications for Program Project grants (P01) aimed at fostering collaborative, multidisciplinary cancer research for the years 2023, 2024, and 2025. Applicants must propose at least three interrelated research projects and an Administrative Core, all centered around a common theme within the expansive field of cancer research, which includes areas such as cancer biology, prevention, diagnosis, treatment, and control. This funding opportunity is crucial for advancing cancer research and enhancing the effectiveness of collaborative efforts, with applications due by May 7, 2026. Interested parties can find more information and application guidelines at the provided link, and inquiries can be directed to NIH Grants Information at grantsinfo@nih.gov.
    Microbial-based Cancer Imaging and Therapy - Bugs as Drugs (R01 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Cancer Institute (NCI), is offering a funding opportunity titled "Microbial-based Cancer Imaging and Therapy - Bugs as Drugs" (PAR-25-107). This initiative invites grant applications that explore the use of bacteria, archaebacteria, bacteriophages, and non-oncolytic viruses to investigate their interactions with tumors and the immune system, aiming to develop innovative strategies for cancer imaging and therapy, particularly for oral cancers. The program encourages multidisciplinary collaboration among experts in microbiology, cancer biology, and immunology to address challenges associated with solid tumors and metastases. Applications will be accepted starting January 5, 2025, with no budget limit, and the project period can extend up to five years. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov.
    Tactical Behaviors for Autonomous Maneuver
    Dept of the Army -- Materiel Command
    The Department of the Army's Materiel Command is offering a funding opportunity through the Tactical Behaviors for Autonomous Maneuver Collaborative Research Program (TBAM-CRP) aimed at enhancing the capabilities of robotic and autonomous systems (RAS) for military operations in complex environments. This program seeks proposals that develop coordinated and adaptive behaviors for small groups of autonomous agents, focusing on innovative maneuver tactics and strategies to operate effectively in multi-domain operations against peer adversaries. The TBAM-CRP is critical for advancing military capabilities, leveraging new technologies in robotics and autonomous systems to improve situational awareness and operational effectiveness on the battlefield. Interested applicants, including institutions of higher education and for-profit organizations, are invited to submit proposals by April 24, 2024, with funding amounts ranging from $100,000 to $2.3 million available per award. For further inquiries, applicants can contact Christopher D. Justice at usarmy.adelphi.devcom-arl.mbx.tbam-crp-questions@army.mil.
    Discovery and Development of Natural Products for Cancer Interception and Prevention (UG3/UH3 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Discovery and Development of Natural Products for Cancer Interception and Prevention" under the cooperative agreement mechanism. This initiative aims to support innovative projects that focus on the discovery and development of novel natural products that are safe, nontoxic, and effective in intercepting or preventing cancer, with a structured approach divided into two phases: the UG3 phase for initial target selection and assay validation, followed by the UH3 phase for large-scale evaluations and pharmacokinetic assessments. The total funding available for this program is $4.5 million over the fiscal years 2024 to 2026, with a deadline for applications set for June 14, 2025. Interested applicants can find more information and contact NIH Grants Information at grantsinfo@nih.gov for inquiries.
    Critical Path Public Private Partnerships Clinical Trials Optional
    Food and Drug Administration
    The Food and Drug Administration (FDA) is forecasting a grant opportunity titled "Critical Path Public Private Partnerships Clinical Trials Optional," aimed at supporting the continuation of existing consortia groups established by the Critical Path Institute. This initiative seeks applications to manage and maintain these groups, fostering innovative projects in research, education, and outreach to enhance drug product innovation and accelerate the development of therapeutics. The grant, which has an award ceiling and floor of $20 million, is expected to result in one award, with applications being accepted for the fiscal year 2024. Interested applicants can contact Terrin Brown at terrin.brown@fda.hhs.gov or (240) 402-7610 for further information.
    BROAD AGENCY ANNOUNCEMENT (BAA) for Extramural Biomedical and Human Performance Research and Development Department of Defense
    Dept. of the Army -- USAMRAA
    The Department of the Army, through the US Army Medical Research Acquisition Activity (USAMRAA), has announced a Broad Agency Announcement (BAA) for Extramural Biomedical and Human Performance Research and Development. This opportunity invites unrestricted applicants to submit proposals aimed at advancing biomedical research and development, with a focus on enhancing human performance. The program is critical for fostering innovation in science and technology, particularly in areas that support the Department of Defense's mission. The estimated total program funding is $10 million, with individual awards ranging from $750,000 to $50 million, and proposals are due by July 31, 2028. For further inquiries, applicants can contact the CDMRP Help Desk at help@eBRAP.org or by phone at 301-682-5507.
    Mechanisms that Impact Cancer Risk with Use of Incretin Mimetics (R21 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a federal grant opportunity titled "Mechanisms that Impact Cancer Risk with Use of Incretin Mimetics (R21 Clinical Trial Not Allowed)." This initiative aims to promote exploratory research into the biological mechanisms by which incretin mimetics, particularly GLP-1 and dual GLP-1/GIP-1 receptor agonists, influence cancer risk, with a focus on understanding their effects beyond diabetes treatment. The funding, which amounts to a maximum of $275,000 over two years, is intended to attract diverse researchers and institutions to fill significant gaps in current cancer biology research. Interested applicants should note that the application submission period begins on January 16, 2025, and can find further details and guidelines at the NIH grants website or by contacting NIH Grants Information at grantsinfo@nih.gov.